Botulinum toxin for the treatment of spasticity in children: Attainment of treatment goals

Journal of Pediatric Orthopaedics Part B

Volumn 16, Issue 4, 2007, Pages 293-296

  Weigl, Daniel M ^a   Arbel, Nili ^a,b   Katz, Kalman ^a   Becker, Tali ^a   Bar On, Elhanan ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Botulinum toxin; Cerebral palsy; Goal Attainment Scale

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; MOTOR PERFORMANCE; PRIORITY JOURNAL; RATING SCALE; SPASTICITY; TREATMENT OUTCOME; CEREBRAL PALSY; CLASSIFICATION; EVALUATION; INFANT; LEG; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LOWER EXTREMITY; MALE; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; TREATMENT OUTCOME;

EID: 34547432991     PISSN: 1060152X     EISSN: 14735865     Source Type: Journal    
DOI: 10.1097/BPB.0b013e328092562b     Document Type: Article

References (16)

1. Carruthers J, Stubbs HA. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. Can J Neurol Sci 1987; 14:42-45.
2. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986; 2:245-247.
3. Ludlow CL, Naunton FR, Sedory SE, Schulz GM, Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 1988; 38:1220-1225.
4. Koman LA, Mooney JF 3rd, Smith B, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop 1993; 13:489-495.
5. Boyd R, Graham HK. Botulinum toxin A in the management of children with cerebral palsy: indications and outcome. Eur J Neurol 1997; 4 (Suppl 2): S15-S22.
6. Palisano RJ, Hanna SE, Rosenbaum PL, Russell DJ, Walter SD, Wood EP, et al. Validation of a model of gross motor function for children with cerebral palsy. Phys Ther 2000; 80:974-985.
7. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997; 39:214-223.
8. Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000; 31:2402-2406.
9. Bakheit AM, Pittock S, Moore AP, Wurker M, Otto S, Erbguth F, Coxon L. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001; 8:559-565.
10. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1966; 46:1306-1310.
11. Boyd RN, Hays RM. Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. Eur J Neurol 2001; 8 (Suppl 5):1-20.
12. Boyd RN, Dobson F, Parrott J, Love S, Oates J, Larson A, et al. The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial. Eur J Neurol 2001; 8 (Suppl 5):109-119.
13. Palisano RJ. Validity of goal attainment scaling in infants with motor delays. Phys Ther 1993; 73:651-660.
14. Wallen MA, O'Flaherty SJ, Waugh MC. Functional outcomes of intramuscular botulinum toxin type A in the upper limbs of children with cerebral palsy: a phase II trial. Arch Phys Med Rehabil 2004; 85:192-200 (Erratum in Arch Phys Med Rehabil 85:862).
15. Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001; 108:1062-1071.
16. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Movement Disord 1994; 9: 213-217.